AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Progress reported in development of new drug delivery device portfolio.
2003 OCT 1 - (NewsRx.com & NewsRx.net) -- Antares Pharma, Inc., (ANTR) announced that it has completed preliminary clinical testing on several of its new device products, and these devices are now available for licensing for use with specific products.
These device products include:
1) The next generation of reusable needle-free injector, Valeo, a smaller and more portable system than current needle-free injectors, designed for use with drugs in cartridge containers, rather than vials, a format that has become more widely used for several patient self-administered products.
2) The Vibex, a prefilled, single-use device incorporating Antares Pharma's proprietary mini-needle technology. The Vibex is designed to deliver products for shorter-term use, intermittent need, or for emergency situations.
3) The Ventrix, a variant of Vibex, designed specifically for physician office based administration of vaccines.
Commenting on the progress of these device products, Peter Sadowski, PhD, VP of ...
- Antares Pharma, Inc. and GeneMedix plc Announce Their Intent to Form a...
- Press release article from: PR Newswire March 25, 2003 700+ words
...Officer and President of Antares Pharma, said, "We are delighted...advantage. We believe that Antares Pharma's device products will be well received by...health marketplace. About Antares Pharma Antares Pharma develops pharmaceutical...
- Antares Pharma Announces Progress in Development of Its New Device Portfolio.
- Press release article from: PR Newswire September 4, 2003 700+ words
Antares Pharma, Inc. (BULLETIN...several of its new device products, and these...products. These device products include...incorporating Antares Pharma's proprietary...progress of these device products, Peter Sadowski...
- Antares Pharma's Licensee Reaches Important Milestone.
- Press release article from: PR Newswire January 19, 2005 700+ words
Antares Pharma's North American Licensee, BioSante...III Clinical Trial for Estradiol Gel Antares Pharma, Inc. announced today that its North...2005. Bio-E-Gel(TM) utilizes Antares Pharma's proprietary Advanced Transdermal...
- Antares Pharma Announces Its Licensee, BioSante Pharmaceuticals, Has Completed...
- Press release article from: PR Newswire May 16, 2003 700+ words
Antares Pharma Inc. announced today that its licensee...menopausal women. Bio-E-Gel utilizes Antares Pharma's proprietary ATD(TM) gel technology...week Phase III clinical trial. Antares Pharma's ATD(TM) Portfolio BioSante...
- Antares Pharma Acquires Intellectual Property for Prefilled Needle-Free...
- Press release article from: PR Newswire November 1, 2001 700+ words
...Free Injection Technology Reflects Antares Pharma's Progress on Strategic Plan MINNEAPOLIS...Switzerland, Nov. 1 /PRNewswire/ -- Antares Pharma, Inc. (Nasdaq: ANTR) today announced...France. As part of the agreement, Antares Pharma has acquired intellectual property...
- Antares Pharma Presents Before the Financial Analysts and Money Managers...
- Press release article from: PR Newswire March 4, 2003 700+ words
Antares Pharma, Inc. , in an after market presentation...Executive Officer and President of Antares Pharma, stated that the Company's goals...agreements in 2003." He also noted that Antares Pharma's financial position has improved...
- Antares Pharma, Inc. and Ferring Pharmaceuticals Announce Extension of Their...
- Press release article from: PR Newswire February 12, 2003 700+ words
Antares Pharma, Inc. and Ferring Pharmaceuticals...VISION, Ferring's trade name for Antares Pharma's Medi-Jector VISION(R) device...access next-generation devices from Antares Pharma to further support the development...
- Antares Pharma Announces its Licensee, BioSante Pharmaceuticals, Recently...
- Press release article from: PR Newswire October 23, 2003 700+ words
Antares Pharma Inc. (BULLETIN BOARD: ANTR) announced...sexual dysfunction. LibiGel utilizes Antares Pharma's proprietary advanced transdermal...identical testosterone that utilizes Antares Pharma's ATD(TM) technology and is designed...
Source: HighBeam Research, Progress reported in development of new drug delivery device...